Literature DB >> 3047062

Effect of carrier selection on immunogenicity of protein conjugate vaccines against Plasmodium falciparum circumsporozoites.

J U Que1, S J Cryz, R Ballou, E Fürer, M Gross, J Young, G F Wasserman, L A Loomis, J C Sadoff.   

Abstract

Conjugate vaccines against the sporozoite stage of Plasmodium falciparum were synthesized by covalently coupling the recombinant protein R32 [with the one-letter amino acid code of MDP-[(NANP)15NVDP]2LR] to tetanus toxoid, cholera toxin, choleragenoid, and Pseudomonas aeruginosa toxin A. Conjugates were produced by using adipic acid dihydrazide as a spacer molecule and carbodiimide as a coupling agent. The molar ratio of R32 to carrier protein ranged from 2.5:1 to 8.4:1. These conjugates were found to be stable, nontoxic, and nonpyrogenic. When adsorbed onto Al(OH)3, all conjugates were capable of inducing anti-R32 antibody. Conjugates made with either cholera toxin or Pseudomonas aeruginosa toxin A were significantly more immunogenic than those constructed with tetanus toxoid or choleragenoid. However, the magnitude of the immune response to the R32 moiety was not governed by the antibody response to the carrier protein.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3047062      PMCID: PMC259624          DOI: 10.1128/iai.56.10.2645-2649.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  23 in total

Review 1.  Developing a human malaria sporozoite vaccine.

Authors:  J F Young; W R Ballou; W T Hockmeyer
Journal:  Microb Pathog       Date:  1987-04       Impact factor: 3.738

2.  Expression of Plasmodium falciparum circumsporozoite proteins in Escherichia coli for potential use in a human malaria vaccine.

Authors:  J F Young; W T Hockmeyer; M Gross; W R Ballou; R A Wirtz; J H Trosper; R L Beaudoin; M R Hollingdale; L H Miller; C L Diggs
Journal:  Science       Date:  1985-05-24       Impact factor: 47.728

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 4.  Development of sporozoite vaccines.

Authors:  R S Nussenzweig; V Nussenzweig
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1984-11-13       Impact factor: 6.237

5.  Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite.

Authors:  N Yoshida; R S Nussenzweig; P Potocnjak; V Nussenzweig; M Aikawa
Journal:  Science       Date:  1980-01-04       Impact factor: 47.728

6.  Development of improved cholera vaccine based on subunit toxoid.

Authors:  J Holmgren; A M Svennerholm; I Lönnroth; M Fall-Persson; B Markman; H Lundbeck
Journal:  Nature       Date:  1977-10-13       Impact factor: 49.962

7.  Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum.

Authors:  J B Dame; J L Williams; T F McCutchan; J L Weber; R A Wirtz; W T Hockmeyer; W L Maloy; J D Haynes; I Schneider; D Roberts
Journal:  Science       Date:  1984-08-10       Impact factor: 47.728

8.  DNA cloning of Plasmodium falciparum circumsporozoite gene: amino acid sequence of repetitive epitope.

Authors:  V Enea; J Ellis; F Zavala; D E Arnot; A Asavanich; A Masuda; I Quakyi; R S Nussenzweig
Journal:  Science       Date:  1984-08-10       Impact factor: 47.728

9.  Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.609

10.  Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection.

Authors:  P Potocnjak; N Yoshida; R S Nussenzweig; V Nussenzweig
Journal:  J Exp Med       Date:  1980-06-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Molecular parasitology: progress towards the development of vaccines for malaria, filariasis, and schistosomiasis.

Authors:  S J Cryz
Journal:  Experientia       Date:  1991-02-15

2.  Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders.

Authors:  Feng Qian; Kelly M Rausch; Olga Muratova; Hong Zhou; Guanhong Song; Ababacar Diouf; Lynn Lambert; David L Narum; Yimin Wu; Allan Saul; Louis H Miller; Carole A Long; Gregory E D Mullen
Journal:  Vaccine       Date:  2008-03-27       Impact factor: 3.641

3.  Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A.

Authors:  L F Fries; D M Gordon; I Schneider; J C Beier; G W Long; M Gross; J U Que; S J Cryz; J C Sadoff
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.609

4.  Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines.

Authors:  S J Cryz; A S Cross; J C Sadoff; E Fürer
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.609

5.  Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates.

Authors:  Feng Qian; Yimin Wu; Olga Muratova; Hong Zhou; Gelu Dobrescu; Peter Duggan; Lambert Lynn; Guanhong Song; Yanling Zhang; Karine Reiter; Nicholas MacDonald; David L Narum; Carole A Long; Louis H Miller; Allan Saul; Gregory E D Mullen
Journal:  Vaccine       Date:  2007-03-13       Impact factor: 4.169

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.